

Special Issue

Prostate Cancer Pathology: Recent Advances and Future Perspectives

Message from the Guest Editor

In recent decades, dramatic changes in the diagnosis and management of prostate cancer have occurred. However, the rise in newly diagnosed cases (especially in younger men) mandates a more accurate pathological diagnosis that will facilitate the distinction of indolent cancers and save patients from unnecessary morbid interventions. Moreover, in the era of precision medicine, molecular pathology techniques and advances allow for more patient-centered and tailored management. However, the clinical and biological heterogeneity of prostate cancer is responsible for ongoing controversies in the pathological evaluation of the disease, ranging from the interpretation of initial biopsies and the reliability of the Gleason scoring system to the controversial utility of emerging biomarkers in the clinical setting. The aim of this Special Issue is to present recent advances in the pathological evaluation, interpretation, and reporting of prostate carcinoma. Both original articles and interesting reviews are welcome to be submitted to this Special Issue to shed light on the continuously evolving landscape of the pathology of prostate cancer and its importance in precise clinical management.

Guest Editor

Prof. Dr. Kostis Gyftopoulos

Department of Anatomy, School of Medicine, University of Patras,
26504 Patras, Greece

Deadline for manuscript submissions

31 May 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/233994

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).